Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Motixafortide - BioLineRx

Drug Profile

Motixafortide - BioLineRx

Alternative Names: 4F-Benzoyl-TN14003; BKT-140; BL-8040; TF-14016; TN-14003

Latest Information Update: 05 Feb 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyoto University
  • Developer Biokine Therapeutics; BioLineRx; Genentech; Merck AG; University of Texas M. D. Anderson Cancer Center
  • Class Antianaemics; Antineoplastics; Cyclic peptides; Peptides
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Pancreatic cancer; Stem cell mobilisation
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Stem cell mobilisation
  • Phase II Acute myeloid leukaemia; Pancreatic cancer
  • Phase I/II Aplastic anaemia; Gastric cancer; Multiple myeloma; Myelodysplastic syndromes; Non-small cell lung cancer
  • No development reported Autoimmune disorders; Chronic myeloid leukaemia; Thrombocytopenia

Most Recent Events

  • 28 Mar 2019 BioLineRx expects to meet with regulatory authorities to discuss future development plans in Acute myeloid leukaemia (Second-line therapy or greater) in the second half of 2019
  • 04 Feb 2019 BL 8040 receives Orphan Drug status for Pancreatic cancer in USA
  • 11 Dec 2018 Phase-II clinical trials in Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater, Inoperable/Unresectable) in Israel (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top